Gregory Horn, MD
Obstetrics & Gynecology · Ocean Springs, MSNPI 1659371128
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,479 of the $3,717 with a category attached, or 66.7%. 37 manufacturers reported payments, led by Coloplast at 24.9% of the total. Reporting peaked in 2022 at $1,331 and has fallen 89.7% since, to $137 in 2025.
Across 122 payments — averaging $30.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$926
- Intuitive Surgical$687
- AbbVie$685
- Astellas Pharma US Inc$113
- Coopersurgical, Inc.$100
- Minerva Surgical, Inc$99
- plus $1K from 31 others
What the payments were for
- Travel & lodging$1,12230%
- Food & beverage$2,47967%
- Education$1163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 6 | $926 |
| Intuitive Surgical | 4 | $687 |
| AbbVie | 44 | $685 |
| Astellas Pharma US Inc | 2 | $113 |
| Coopersurgical, Inc. | 1 | $100 |
| Minerva Surgical, Inc | 1 | $99 |
| Organon | 6 | $96 |
| Baxter Healthcare | 2 | $86 |
| Johnson & Johnson | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $73 |
| Mayne Pharma Commercial LLC | 5 | $64 |
| Therapeuticsmd, Inc. | 4 | $61 |
| Vertex | 3 | $52 |
| Merck | 3 | $47 |
| Sage Therapeutics, LLC | 2 | $45 |
| Avion Pharmaceuticals | 3 | $39 |
| Scynexis, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $37 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Roche Diagnostics Corporation | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $33 |
| Mylan Pharmaceuticals Inc. | 2 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $28 |
| Exeltis, USA Inc. | 1 | $24 |
| Bard Access Systems, Inc. | 1 | $24 |
| Axonics, Inc. | 1 | $22 |
| Davol Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Nevro Corp. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Agile Therapeutics, Inc. | 1 | $14 |
| Next Science LLC | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Lupin Inc. | 1 | $12 |
| Meditrina | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,717 in reported general payments places this provider in the 80th percentile of 318 obstetrics & gynecology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 15 | $12,728 |
| MyrbetriqMirabegron | 14 | $7,076 |
| PremarinEstrogens, Conjugated | 14 | $6,425 |
| Estradiol | 222 | $2,671 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 20 | $1,553 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 46 | $940 |
| Medroxyprogesterone Acetate | 41 | $536 |
| ValacyclovirValacyclovir Hcl | 21 | $534 |
| Fluconazole | 41 | $184 |
| Alprazolam | 63 | $155 |
| Ondansetron Hcl | 15 | $151 |
| Acyclovir | 12 | $65 |
| Metronidazole | 12 | $62 |
| Fluoxetine Hcl | 12 | $34 |
| Alendronate Sodium | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $36 | $12,72815 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $7,07614 claims |
| PfizerPremarin | $18 | $6,42514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 318 obstetrics & gynecology providers in Mississippi.
Other obstetrics & gynecology in Ocean Springs
- Bradley SamsOcean Springs$9K
- Sheli SamsOcean Springs$4K
- Robert DesantisEllisville$212K
- Lori FultonJackson$102K
- Sheila BouldinJackson$56K
- Melissa BarnettTupelo$50K
- Ahmet BedestaniFlowood$41K
- Stacey KreherBay St. Louis$40K
- Joseph McGeheeTupelo$35K
- Elizabeth TarsiTupelo$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.